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Mitochondria play an important role in controlling the life and death of a cell. Consequently, mitochondrial dysfunction leads to a range of
human diseases such as ischemia–reperfusion injury, sepsis, and diabetes. Although the molecular mechanisms responsible for mitochondria-
mediated disease processes are not fully elucidated yet, the oxidative stress appears to be critical. Accordingly, strategies are being developed for
the targeted delivery of antioxidants to mitochondria. In this review, we shall briefly discuss cellular reactive oxygen species metabolism and its
role in pathophysiology; the currently existing antioxidants and possible reasons why they are not effective in ameliorating oxidative stress-
mediated diseases; and recent developments in mitochondrially targeted antioxidants and their future promise for disease treatment.
D 2005 Elsevier B.V. All rights reserved.Keywords: Reactive oxygen species; Antioxidant; Mitochondria; Mitochondria membrane potential; Oxidative stress1. Introduction
There is a continuing search for better and more effective
antioxidants. The recent recognition of mitochondria as an
arbiter of the life and death of cells has drawn awareness to
the need to develop antioxidants and other cytoprotective
agents targeted to mitochondria. Physiologically, mitochondria
perform a variety of key cellular regulatory processes,
including ATP production, intracellular Ca2+ regulation,
reactive oxygen species (ROS) generation and detoxication,
and apoptosis [1]. Mitochondria use approximately 90% of
the consumed O2 for oxidative phosphorylation and ATP
synthesis. Thus, the proteins involved in the mitochondrial
electron transport chain are probable sites for ROS genera-
tion. Intracellular glutathione, glutathione peroxidase, gluta-
thione transferases, catalase, superoxide dismutase, and a
variety of other antioxidant defenses keep ROS concentrations
in check, which allows cells to function homeostatically and
to prevent oxidative stress [2–6]. A shift in the balance
between ROS generation and destruction to overproduction or
decreased detoxication is associated with chronic diseases [7].0925-4439/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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mitochondria-targeted antioxidants has increased steadily.
This is exemplified by recent studies showing that triphenyl-
phosphonium-based antioxidants and amino acid- and pep-
tide-based antioxidants protect mitochondria against oxidative
insult. One can envision that the future efforts in exploiting
the unique biophysical and biochemical properties of mito-
chondria for the targeted delivery of cytoprotective agents
will increase rapidly.
2. Cellular mechanisms of ROS generation
The etiology of a range of diseases is associated with the
generation of excess ROS. Steady-state maintenance of ROS/
antioxidant ratio is, however, essential for cell signaling. ROS
generated in cells include the superoxide anion radical (O2
S),
hydrogen peroxide (H2O2), hypochlorous acid (HOCl),
hydroxyl radical (OH
S
), and singlet oxygen (1O2). These
ROS are formed as a consequence of endogenous enzymatic
and nonenzymatic reactions within the cell and within
mitochondria. ROS may also be formed in response to
external stimuli and chemicals. Cellular sources of ROS are
shown in Fig. 1.
ROS are generated by biochemical reactions in the cell.
Indeed, leakage of electrons from the mitochondrial electron1762 (2006) 256 – 265
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Fig. 1. Cellular sources of ROS. Mitochondrial sources of ROS include the electron transport chain (ETC), TCA cycle, and monoamine oxidase (MAO) at the
outer membrane. Superoxide (O2
S
) does not readily cross membranes, but manganese superoxide dismutase (MnSOD) converts intramitochondrial O2
S
to
hydrogen peroxide (H2O2), which can diffuse out of mitochondria. Cytosolic O2
S
is converted to H2O2 by copper-zinc SOD (Cu/Zn SOD). Cytosolic sources
of ROS include xanthine oxidase (XO) and cytochrome P450 reductases. Nitric oxide synthase (NOS) catalyzes the synthesis of nitric oxide (NOS), which may
react with O2
S
to give the oxidant peroxynitrite (ONOO). Under certain conditions, NOS may also generate O2
S
. Myeloperoxidase (MPO, and also
eosinophil peroxidase, EPO) use H2O2 and halides (Cl
, Br) to make hypohalous acids (HOCl, HOBr). H2O2 can also undergo Fenton chemistry with metals,
such as iron, to generate the hydroxyl radical (OHS). Membrane-linked sources of ROS include the NADPH oxidases (NOX), and the cytochromes P450.
Moreover, lipoxygenase (LOX), cyclooxygenase (COX), and ROS can generate oxidized lipids (LOX) inside membranes. ROS can also arise outside the cell,
including singlet oxygen (1O2) generation by UV irradiation, environmental ozone (O3), or other ROS and RNS in pollutants, such as cigarette smoke.
Chemicals, such as quinones (Q) and nitroaromatics, may undergo redox cycling by intracellular NAD(P)H dehydrogenases to generate ROS.
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mitochondrial ROS, particularly O2
S [8]. Moreover, the
TCA cycle enzymes a-ketoglutarate dehydrogenase and the
pyruvate dehydrogenase complex also generate O2
S and H2O2
[9]. O2
S is also generated by NADPH oxidase, which is found
in phagocytic and nonphagocytic macrophages [10], and by
xanthine dehydrogenase/oxidase (XO, Fig. 1) [11]. H2O2
peroxide is produced by mitochondrial monoamine oxidase
(MAO, Fig. 1) [12] and by the superoxide dismutase (MnSOD
and Cu/ZnSOD, Fig. 1)-catalyzed dismutation of O2
S [13]. In
addition, peroxisomal acyl-CoA oxidases also generate H2O2
[14]. The myeloperoxidase-catalyzed generation of hypochlor-
ous acid is an important line of defense against invading
microorganisms (MPO, Fig. 1) [15].
There is no known enzymatic route to hydroxyl radical, but
it is produced by the Haber–Weiss reaction in the presence of
transition metals, particularly iron. 1O2 may be formed by
photodynamic processes or from the reaction of HOCl with
H2O2.
Although not the focus of this review, reactive nitrogen
species (RNS, Fig. 1) have also been implicated in cell
damage and death. Nitric oxide synthase (NOS, Fig. 1)
catalyzes the synthesis of the radical species nitric oxide(NO
S
, Fig. 1), which may react with O2
S to give peroxy-
nitrite (ONOO, Fig. 1).
ROS generation may also be associated with external
stimuli. UV and high-energy irradiation (UV, Fig. 1), the
metabolism of some xenobiotics, air pollutants (O3, Fig. 1), and
the redox cycling of quinones (Q, Fig. 1) and nitroaromatics
are all associated with ROS generation.
The balance between these sources of ROS depends on the
physiologic and pathophysiologic states of the organism, and
it is often difficult to pinpoint the source of ROS generation.
It is, however, known that ROS exert important regulatory
functions [16]. Hence, a basal or tonal concentration of ROS,
especially at the level of the mitochondrion, is essential for
basic cell signaling processes. In other words, all ROS are not
created equal, and compartmentalization and concentration
gradients are highly important. Although a full discussion of
ROS-dependent cell signaling is beyond the scope of this
review, it is important to recognize that the abolishment all
cellular ROS by vigorous use of antioxidants may not be
beneficial and, indeed, may prove harmful. The requirement
for a basal ROS tone for cell signaling may explain why
many antioxidant-based therapies have failed. A more subtle
approach is required, in which specific populations of ROS
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targeting of antioxidants.
3. Oxidative stress in disease etiology
Traditionally, mitochondrial diseases have focused on
mitochondrial respiratory-chain diseases associated with muta-
tions of mitochondrial DNA [17]. For instance, a maternal
inheritance of a point mutation in the complex I gene (ND4)
causes Leber’s hereditary optic neuropathy (LHON) [18]. The
diseases that result from familial mitochondrial DNA deletions
and mutations are not as common as those that result from
nuclear DNA defects. This may be because mitochondria
contain several copies of their genome; hence, continuous
fusion of mitochondria mixes the modified genes with the
normal genes so that deleterious effects are reduced. Moreover,
the continuous fission of mitochondria increases the likelihood
that modified mitochondrial genes are removed by autophagy
[19].
The recent realization that acute and chronic stresses to the
cells leads to structural and functional impairments of
mitochondria has redefined the role of mitochondria in disease
etiology. Mitochondrial dysfunction triggers signaling cascades
for necrosis and apoptosis of cells and results in organ failure
and diseases. Although the list of mitochondria-related diseases
is growing rapidly and includes, among others, cancer, heart
failure, diabetes, obesity, stroke, neurodegenerative diseases,
and aging, they all share the common features of disturbances
of mitochondrial Ca2+, ATP, or ROS metabolism [20]. For
instance, a number of experimental observations indicates that
cancer cells show noticeable variation in their metabolic
regulation and mitochondrial morphology and physiology
compared with normal cells [21,22]. Interestingly, antioxidants
have been used to increase efficacy of anticancer therapeutic
agents by reducing their adverse effects on normal cells [23].
Similarly, studies show that mitochondrial dysfunction con-
tributes to the progression of neurogenerative diseases, e.g.,
Parkinson’s disease, and stroke [24,25]. Myocardial ischemia–
reperfusion injury also results in mitochondrial Ca2+ overload
that subsequently leads to uncontrollable ROS generation and
opening of mitochondrial permeability transition pore [20].
Therefore, compounds that minimize mitochondrial Ca2+
overload, decrease mitochondrial ROS accumulation, and
improve mitochondrial energy production all have the potential
for treating the above-mentioned diseases.
4. Types of antioxidants and mechanisms of antioxidant
actions
The term antioxidant is not readily defined and, as used in
the literature, may refer to a range of compounds with a range
of mechanisms of action. Halliwell [26] has proposed this
useful definition: ‘‘an antioxidant is any substance that, when
present at low concentrations compared to those of an
oxidizable substrate, significantly delays or prevents oxidation
of that substrate.’’ There is an abundance of oxidizable
substrates in the cell, including proteins, lipids, carbohydrates,and DNA. Thus, antioxidants may function to prevent the
formation of or to detoxify free radicals, to scavenge ROS or
their precursors.
Types of antioxidants include, for example, antioxidant
vitamins (e.g., ascorbic acid, a-tocopherol, h-carotene), inor-
ganic antioxidants (e.g., selenium), synthetic antioxidants (e.g.,
butylated hydroxyanisole [BHA], butylated hydroxytoluene
[BHT], propyl gallate, 2,4,6-trimethylphenol), and a range of
plant-derived polyphenols.
Mechanisms of antioxidant action can best be understood in
the context of their chemical and biochemical effects on ROS.
Lipid-derived oxygen- and carbon-centered free radicals are a
major class of oxidants. Three processes are involved in the
formation of lipid-derived free radicals: initiation, propagation,
and termination. Chain-breaking antioxidants interrupt this
process by preventing propagation of the radical chain or by
terminating the radical chain. a-Tocopherol is a classical
example of a chain-breaking antioxidant. ROS include the
odd-electron radical species O2
S and OHS and the even-
electron species H2O2, HOCl, and
1O2. The antioxidant
enzyme superoxide dismutase catalyzes the conversion of
O2
S to H2O2 and O2; this is important because O2S may give
rise to the OH
S
via the Haber–Weiss reaction. H2O2 may be
detoxified by the Se-dependent glutathione peroxidase (GPx)
(the glutathione disulfide formed in the reaction is reduced to
glutathione by NADPH-dependent glutathione reductase (GR))
and by catalase. The detoxication of H2O2 is particularly
important, because reaction of H2O2 with transition metals
(e.g., ferrous iron) may lead to the formation of the OH
S
. No
detoxification system for the OH
S
is known; hence, the
prevention of its formation is a critical antioxidant process.
Similarly, no detoxication system for HOCl is known.
In summary, a range of natural and synthetic antioxidants is
available, and their mechanisms of action are mostly known.
Because of the presumed role of oxidative stress in cardiovas-
cular disease and a number of other chronic diseases, a number
of human clinical trials have been conducted with antioxidants,
particularly vitamin E. The results of these clinical trials have,
however, failed to show consistent and significant clinical
benefit, and there is some concern that high-dose vitamin E
supplementation may be harmful [27]. It is possible that
carefully designed and conducted randomized clinical trials
may show that antioxidant supplementation is beneficial. One
plausible explanation for the failure of antioxidants to show
beneficial effects is that these antioxidants do not accumulate
preferentially in the mitochondria, the major site of ROS
generation.
5. Antioxidants targeted to mitochondria
Mitochondria are attractive targets for drug-delivery strate-
gies because of their roles in cellular energy metabolism,
programmed (apoptotic) cell death, Ca2+ homeostasis, and cell
signaling. Moreover, mutations in mitochondrial DNA are
associated with a range of human diseases, again making
mitochondria attractive targets for mitochondrial gene therapy.
Hence, there is considerable interest in developing strategies to
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mitochondria (for reviews, see [28–30]).
A range of possibilities is available for the selective delivery
of drugs to mitochondria, including targeting based on biophy-
sical properties of mitochondria, e.g., the high negative internal
potential, targeting based on the unique mitochondrial localiza-
tion of enzymes that catalyze the release of drugs from prodrugs,
and targeting based on transporter-dependent delivery of
prodrugs (Fig. 2).
The mitochondrial respiratory chain participates in transfer of
electron to O2. This electron transport generates a proton
gradient that is used to drive the production of ATP by ATP
synthase. Thus, a negative potential of 150–180mVis generated
across the inner mitochondrial membrane. (The mitochondrial
outer membrane is permeable to small molecules, and thus the
inner membrane represents the major barrier for drug delivery to
the mitochondria.) This high potential gradient across the
mitochondrial inner membrane can be exploited to deliver
lipophilic cations to mitochondria. According to the Nernst
equation, a 61.5-mV hyperpolarization in the mitochondria
membrane potential should result in a 10-fold increase in the
concentration of the lipophilic monovalent cations inside
mitochondria at equilibrium. Therefore, the lipophilic cations
may accumulate in the mitochondrial matrix at concentrations
100- to 1000-fold higher than in the cytosol. This knowledge
was adopted to develop cationic compounds, such as rhodamine
123 and triphenylphosphonium (TPP+) for mitochondrial
membrane potential determinations. Murphy and coworkers
have extended this concept to develop a series of cationic
antioxidants that preferentially accumulate in mitochondria [31].
The aim of this section of the review is to discuss
mitochondrially targeted antioxidants. The mitochondrial tar-
geting of therapeutic agents is, to be sure, not limited to
antioxidant compounds, and Weissig and coworkers [30] have
nicely summarized the scope of strategies for targeting low
molecular-weight compounds to mitochondria.
5.1. Triphenylphosphonium-based, mitochondrially targeted
antioxidants
5.1.1. MitoVit E, [2-(3,4-dihydro-6-hydroxy-2,5,7,8-tetra-
methyl-2H-1-benzopyran-2-yl)ethyl]triphenylphosphonium
bromide
MitoVit E was synthesized to test the concept that the
delivery of an antioxidant to mitochondria should selectively
prevent mitochondrial oxidative damage [32]. MitoVit E is
rapidly taken up by energized mitochondria, and the uptake
persists for at least 15 min. As expected, dissipation of the
mitochondrial membrane potential with FCCP results in the
rapid loss of MitoVit E from mitochondria. Accumulation
ratios (mitochondria/cytoplasm) of 5000–6000 are achieved
after incubating mitochondria with 1–20 AM MitoVit E;
uptake decreases at 50 AM MitoVit E (Fig. 3).
MitoVit E protects isolated rat liver mitochondria from iron/
ascorbate- and tert-butylhydroperoxide-induced oxidative dam-
age, as measured by decreased lipid peroxidation (thiobarbituric
acid reactive species). The protection against tert-butylhydro-peroxide-induced oxidative damage afforded by MitoVit E was
abolished when the mitochondrial membrane potential was
dissipated with FCCP, and the analog triphenylphosphonium
bromide failed to provide protection against oxidative damage.
The cellular uptake of MitoVit E was studied in human
osteosarcoma 143B cells. Uptake is rapid, and a steady-state
concentration is achieved in approximately 60 min, but less
(¨60%) uptake is observed in U0 cells, which lack mitochon-
drial DNA, derived from the 143B cell line. The distribution of
MitoVit E was studied in cells fractionated by digitonin
treatment; approximately 91% of the accumulated MitoVit E
was colocalized with the matrix enzyme citrate synthase.
Finally, MitoVit E was cytotoxic at concentrations greater than
50 AM.
The effect of MitoVit E on mitochondrial ROS in TNF-
induced apoptosis has been investigated in Jurkat and U937
cells [33]. MitoVit E reduces H2O2-induced caspase-3 activity
in Jurkat cells. The cleavage and activation of caspase-8 after
incubation with TNF were not affected by MitoVit E, but the
activation of caspase-3 was increased. In addition, increased
cleavage of Bid and an increased release of cytochrome c from
mitochondria were observed in cells incubated with TNF in the
presence of MitoVit E. Further studies showed that MitoVit E
accelerated TNF-induced apoptosis by increasing the nuclear
localization of NF-nB. These findings demonstrate that
mitochondrial ROS generation is a component of the TNF
signal-transduction pathway during apoptosis.
Friederich ataxia (FRDA) is an inherited nervous-system
disease that is associated with the decreased expression of the
mitochondrial protein frataxin. Frataxin is involved in mito-
chondrial iron homeostasis, and decreased expression of frataxin
leads to oxidative stress and decreased mitochondrial respiratory
chain function [34]. Further evidence for a role of oxidative
stress in FRDA is the finding that long-term treatment of FRDA
subjects with coenzyme Q and vitamin E leads to improvement
in mitochondrial energy synthesis and in cardiac function [35].
MitoVit E prevents oxidative-stress-induced cell death in
cultured fibroblasts from FRDA subjects [36]. Indeed, MitoVit
E is 350-fold more potent than the water-soluble vitamin E
analog trolox, indicating that mitochondrially targeted antiox-
idants may ultimately prove useful in the treatment of FRDA.
The effectiveness of MitoVit E in preventing oxidative
damage to mitochondria and blocking apoptosis has been
studied in bovine aortic epithelial cells (BAEC) [37]. MitoVit E
(1 AM) decreased H2O2- and lipid peroxidation-induced ROS
generation; in addition, MitoVit E inhibited cytochrome c
release, caspase-3 activation, DNA fragmentation, inactivation
of complex I and aconitase, overexpression of transferrin
receptor, and mitochondrial iron uptake and restored the
mitochondrial membrane potential and proteosomal activity.
5.1.2. MitoQ, a mixture of
10-(6V-ubiquinolyl)decyltriphenylphosphonium bromide
(Fig. 3) and 10-(6V-ubiquinonyl)decyltriphenylphosphonium
bromide
Because of the known antioxidant properties of ubiqui-
none, studies were undertaken to prepare and test a triphe-
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ubiquinol (mitoquinol) and ubiquinone (mitoquinone), MitoQ
[38].Fig. 3. Structures of triphenylphosphonium-based, mitochondrially targeted an
benzopyran-2-yl)ethyl]triphenylphosphonium bromide; MitoQ, 10-(6V-ubiquinoly
oxidoimino]methyl]phenoxy]butyl]-triphenylphosphonium bromide; MitoPeroxidase
iodide.Mitoquinone is reduced to mitoquinol and mitoquinol is
oxidized to mitoquinone by beef heart mitochondrial mem-
branes, indicating redox cycling of the targeted compoundstioxidants. MitoVit E, [2-(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-
l)decyltriphenylphosphonium bromide; MitoPBN, [4-[4-[[(1,1-dimethylethyl)
, 2-[4-(4-triphenylphosphoniobutoxy)phenyl]-1,2-benzisoselenazol)-3(2H)-one
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up by energized mitochondria; the maximum accumulation
ratio of MitoQ is approximately 500–600. The addition of
FCCP results in the efflux of MitoQ from mitochondria. The
intramitochondrial localization of MitoQ was also studied; the
data indicate that MitoQ is taken up by energized mitochon-
dria and is adsorbed onto the matrix face of the inner
mitochondrial membrane. MitoQ is also taken up by 143B
osteosarcoma cells over 20–40 min, and addition of FCCP
reduces uptake. Further distribution studies showed that about
one half of the MitoQ taken up by cells was localized in the
mitochondrial fraction.
Concentrations of MitoQ greater than 25 AM resulted in a
loss of the mitochondrial membrane potential, whereas 10 AM
MitoQ had little effect. MitoQ was cytotoxic to 143B cells at
concentrations of 25–50 AM.
MitoQ prevents the H2O2-induced oxidation of cis-parinaric
acid and the ferrous iron-induced formation of malondialde-
hyde. MitoQ (1 AM) blocks H2O2-induced caspase activation
and apoptotic cell death in Jurkat cells, but has no effect on
staurosporine-induced apoptosis in Jurkat cells or TNF-a-
induced apoptosis in WEHI 164 cells.
Studies were conducted to determine the role of hydropho-
bicity in the uptake of MitoQ analogs by mitochondrial
membranes [39]. In these studies, analogs were prepared in
which the length of the hydrocarbon chain separating the
triphenylphosphonium and ubiquinol moieties was 3, 5, 10,
and 15 methylene units. As expected, the octan-1-ol/saline
partition coefficient increased as the chain length was
increased. Similarly, the mitochondrial uptake ranged from
negligible for MitoQ3 to nearly complete for MitoQ15.
Although all analogs showed antioxidant effects, MitoQ10
and MitoQ15 showed the highest efficacy in blocking ferrous
iron-induced lipid peroxidation.
The studies on chain-length analogs of MitoQ have been
extended to investigate their interactions with the mitochon-
drial respiratory chain and ROS [40]. MitoQ10 failed to restore
respiration in Saccharomyces cervisiae strain DCOQ2, which
is not competent to synthesize CoQ, whereas exogenous CoQ6
restored respiration; this is attributed to a failure of complex III
to oxidize MitoQ analogs. MitoQ analogs are reduced by
complex II and glycerol 3-phosphate dehydrogenase, and the
rate of reduction increases as the chain length is increased from
MitoQ3 to MitoQ10. The facile reduction of MitoQ10 affords
antioxidant protection against lipid peroxidation, ONOO, and
O2
S. Finally, the autooxidation of ubiquinols generates O2S,
but O2
S generation with MitoQ10 was minimal but did lead to
the generation of H2O2 and the consumption of NO
S
.
MitoQ was used to investigate nucleotide-sensitive mito-
chondrial proton transport through uncoupling proteins (UCP)
[41]. Superoxide-induced uncoupling was prevented by MitoQ
(and MitoVit E), but not by the untargeted antioxidants
ubiquinone, decylubiquinone, vitamin E, or trolox.
Because of the role of oxidative damage telomere shorten-
ing and, thus in senescence and aging, the effect of MitoQ on
telomere shortening was investigated [42]. MitoQ (50–100
nM) is cytostatic to MRC-5 fibroblasts, and concentrations of10–20 nM MitoQ requires an adaptation period of at least 1
week. Incubation of cells under hyperoxic conditions (40%
oxygen) results in an increase in 2V,7V-dichlorofluorescein
fluorescence that was reduced by MitoQ. Incubation of
MRC-5 cells with MitoQ elongated the replicative lifespan
by approximately 40%. Finally, MitoQ treatment reduces
hyperoxia-induced telomere shortening, indicating that reduc-
tion of oxidative stress slows telomere shortening and prolongs
replicative lifespan of cells.
The effect of MitoQ on cardiac ischemia–reperfusion
injury, which is associated with mitochondrial oxidative
damage, has been investigated a rat model [43]. Rats were
given drinking water that contained 500 AM MitoQ for 14
days; as observed previously, no treatment-related effects on
behavior or gross pathology were noted [44,45]. At the end of
the treatment period, the hearts were removed and perfused in a
Langendorff apparatus, which allowed assessment of ventric-
ular contractile function and left ventricular developed pressure
(LVDP). After equilibration, the hearts were subjected to 30
min of global zero-flow ischemia followed by normoxic
reperfusion. MitoQ affords significant protection against
ischemia–reperfusion-induced decreases in LVDP, left ventric-
ular pressure against time (dP/dt max), coronary blood flow,
and heart rate, whereas little or no benefit was found with the
nontargeted ubiquinone (Q3OH) or triphenylmethylphospho-
nium bromide. The protective effects of MitoQ were confirmed
by morphological analysis. Mitochondrial function was
assessed in heart mitochondria from control and MitoQ-treated
rats. MitoQ protects against the ischemia–reperfusion-induced
decreases in the respiratory control ratio (RCR), damage to
complex I, and decreases in aconitase activity. The amount of
MitoQ in the hearts of treated rats is approximately 20 pmol
MitoQ/g wet weight, which corresponds to a concentration of
100–200 nM MitoQ.
5.1.3. MitoPBN, [4-[4-[[(1,1-dimethylethyl)oxidoimino]-
methyl]phenoxy]butyl]-triphenylphosphonium bromide (Fig. 3)
Nitrones and phenyl tert-butylnitrone (PBN) in particular
have been investigated as neuroprotective agents and anti-
oxidants. Although PBN reacts readily with carbon-centered
radicals, it apparently does not function as a chain-breaking
antioxidant and does not react with superoxide [46]. PBN
exerts protective effects in a range of animal models,
including protection against endotoxin shock, protection
against ischemia–reperfusion injury, and neuroprotection in
experimental models of neurodegeneration and also increases
the life span of mice and rats [47,48]. The mechanism
whereby PBN exerts these effects has often been attributed to
an antioxidant effect, but some evidence supports a role for
PBN in inhibiting the expression of proinflammatory genes
and cytokines.
Because of the selectivity of PBN in reacting with carbon-
centered radicals, a mitochondrially targeted analog, i.e.,
MitoPBN, was prepared to dissect the roles of ROS in the
activation of uncoupling proteins (UCPs) [49]; previous studies
show that MitoVit E and MitoQ block superoxide-induced
activation of UCPs [41]. MitoPBN was rapidly taken up by
Fig. 4. Structures of antioxidant SS tetrapeptides. SS-02, Dmt–D-Arg–Phe–
Lys–NH2; SS-20, Phe–D–Arg–Phe–Lys–NH2; SS-31, D-Arg–Dmt–Lys–
Phe–NH2; Dmt, 2V,6V-dimethyltyrosine.
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MitoPBN amounted to 2.2–4.0 mM; the accumulated
MitoPBN was released after addition of FCCP.
MitoPBN (250 nM) blocks the O2
S-induced activation of
UCPs, but 10 AM PBN was required to block activation of
UCPs. MitoPBN failed to block hydroxynonenal-induced
activation of UCPs. A series of experiments showed that
MitoPBN does not block UCP activation by reacting with O2
S,
OH
S
, or ferrous iron.
5.1.4. MitoPeroxidase, 2-[4-(4-triphenylphosphoniobutoxy)-
phenyl]-1,2-benzisoselenazol)-3(2H)-one iodide (Fig. 3)
Ebselen is an organoselenium compound that shows
antioxidant effects through its glutathione peroxidase-like
action [50]. It has been used extensively to study oxidative
phenomena in experimental systems and has been used in
clinical studies of stroke and inflammatory diseases. To explore
the peroxidase-mimetic effects of ebselen in mitochondria,
MitoPeroxidase, a mitochondrially targeted analog of ebselen,
was prepared [51]. MitoPeroxidase and ebselen (50 AM) inhibit
mitochondrial respiration and decrease the mitochondrial
membrane potential. The binding of MitoPeroxidase to isolated
mitochondria was studied with a TPP+-sensitive electrode.
Binding of MitoPeroxidase to mitochondria is rapid, and the
addition of deenergized mitochondria decreases the concentra-
tion of free MitoPeroxidase. To investigate whether binding to
mitochondria is associated with the selenol (R-SeH) form of
MitoPeroxidase, the selenol was reacted with iodoacetamide to
block the selenol group and give carboxyamidomethylated
MitoPeroxidase (CAM-MitoPeroxidase). (Studies with bovine
heart mitochondrial membranes showed that MitoPeroxidase
reacts with protein thiols in the membranes.) CAM-MitoPer-
oxidase also became bound to mitochondria, but to a lesser
extent than that observed with MitoPeroxidase, and the uptake
of CAM-MitoPeroxidase is reversed by addition of FCCP.
Also, MitoPeroxidase and ebselen degrade phospholipid
hydroperoxides and prevent Fe2+/H2O2-induced lipid perox-
idation in intact mitochondria, but these antioxidant effects
require glutathione or thioredoxin to generate the selenol form
of MitoPeroxidase and ebselen. Both MitoPeroxidase and
ebselen decrease 2-deoxyglucose- or H2O2-induced caspase-3-
associated apoptosis in RBL-2H3 cells.
5.2. Amino acid- and peptide-based, mitochondrially
targeted antioxidants
5.2.1. SS tetrapeptides (Fig. 4)
The SS tetrapeptides are aromatic–cationic peptides that
bear the structural motif of alternating aromatic and basic
amino acid residues along with a 2V,6V-dimethyltyrosine (Dmt)
residue [52]. The antioxidant properties of these tetrapeptides
apparently stem from the presence of Dmt; the related
compound 3,5-dimethylphenol is a known phenolic antioxidant
[53]. The SS tetrapeptides were originally prepared in an
attempt to develop centrally acting opioid analgesics [54–56].
The compounds studied included Dmt–D-Arg–Phe–Lys–
NH2 (SS-02), Phe–D-Arg–Phe–Lys–NH2 (SS-20) (a tetra-peptide that lacks the antioxidant Dmt), and D-Arg–Dmt–
Lys–Phe–NH2 (SS-31); Dmt–D-Arg–Phe–atnDap–NH2
(SS-19), a fluorescent analog in which h-anthraniloyl-l-a,h-
diaminoproprionic acid replaces Lys4, was prepared to study
mitochondrial and cellular uptake.
SS-02 scavenges H2O2 and inhibits the oxidation of linoleic
acid and low-density lipoproteins (LDL), thereby demonstrat-
ing the antioxidant properties of these tetrapeptides [52]. SS-
31, which contains the same amino acid residues as SS-02 but
in a different sequence, shows antioxidant properties similar to
SS-02, but the analog SS-20, which lacks the Dmt residue, did
not demonstrate antioxidant activity. SS-02 is taken up by
Caco-2 cells; the intracellular concentration is approximately
10-times the extracellular concentration. Confocal imaging
studies of Caco-2 cells show that intracellular distribution of
SS-19 resembles that of MitoTracker TMRM, which localizes
in mitochondria. The uptake of [3H]SS-02 and SS-19 by
isolated mouse liver mitochondria is rapid, and the mitochon-
drial accumulation amounts to approximately 105-fold. Incu-
bation of mitochondria with FCCP reduces the uptake of
[3H]SS-02 and SS-19 by approximately 20%, indicating a
partial potential-dependent uptake. Digitonin treatment of the
Fig. 5. Structures of choline esters of glutathione and N-acetyl-l-cysteine.
MitoGSH, choline (glycinate) ester of glutathione; MitoNAC, choline ester of
N-acetyl-l-cysteine.
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in the mitoplast (inner mitochondrial membrane and matrix).
A panel of in vitro experiments showed that SS-31 and SS-
02 protect neuronal N2A cells from tert-butylhydroperoxide-
induced ROS generation and cytotoxicity, Caco-2 cells against
3-nitropropionic acid-induced mitochondrial depolarization,
and isolated mitochondria from hydrogen peroxide-induced
ROS generation and calcium-induced swelling and mitochon-
drial permeability transition (MPT); SS-20 lacks antioxidant
properties in these experiments. Finally, SS-02 and SS-31
protect against the loss of contractile force induced by 30 min
of global ischemia in the isolated perfused guinea pig heart,
whereas SS-20 failed to prevent the loss of contractile function
associated with reperfusion. These studies show that these cell-
permeable tetrapeptides are effective antioxidants in a range ofFig. 6. Glutathione choline ester (MitoGSH) delays H2O2-induced mitochondrial d
myocytes. The figure shows time-lapse traces of tetramethylrhodamine methyl est
absence (control panels) and presence of MitoGSH (MitoGSH panels). In MitoGS
addition of H2O2. TMRM was used as an indicator of mitochondrial membrane pote
nm. Fluorescence images were recorded every 2 min to avoid photobleaching and ph
in 34 min. MitoGSH pretreatment delayed this significant loss of TMRM fluorescein vitro studies. Moreover, these small peptides do not require
the attachment of a cationic molecule to be accumulated
preferentially in mitochondria. Thus they may have the
advantage in exerting effective antioxidant action in depolar-
ized mitochondria.
5.2.2. Choline esters of glutathione and
N-acetyl-l-cysteine
Glutathione (l-g-glutamyl-l-cysteinylglycine) is the most
abundant nonprotein thiol in cells. Glutathione plays a critical
role in antioxidant defense mechanisms and in the detoxifica-
tion of endobiotic and xenobiotic electrophiles [57]. Mitochon-
dria are, however, not competent to synthesize glutathione, and
glutathione is transported from the cytoplasm to the mitochon-
dria by a high-affinity, low capacity transporter (Km60 AM,
Vmaxnmol/min/mg protein) [58]. Present evidence indicates
that the dicarboxylate and 2-oxoglutarate carriers serve to
transport glutathione into mitochondria [59,60]. The mitochon-
drial glutathione pool amounts to approximately 15% of total
cellular glutathione [61], but the mitochondrial glutathione pool
plays a critical role in cytoprotection [62,63]. Hence, strategies
to increase the mitochondrial content of glutathione and other
thiol-based antioxidants may serve to protect mitochondria,
along with cells and organs, against oxidative damage.
Accordingly, glutathione choline ester and N-acetyl-l-
cysteine choline ester were prepared as mitochondrially
targeted antioxidants (Fig. 5) (S.-S. Sheu, V.K. Sharma, D.
Nauduri, L. Xu, P.S. Brookes, and M. W. Anders, unpublished
work). These hydrophilic antioxidants were designed to exploitepolarization, as measured by TMRM fluorescence, in neonatal rat ventricular
er (TMRM) fluorescence from myocytes incubated with 50 AM H2O2 in the
H panels, the cells were incubated with 50 AM MitoGSH for 30 min before
ntial and was excited at 555 nm and fluorescence emission was detected at 590
ototoxicity. Treatment of H2O2 caused a significant loss of TMRM fluorescence
nce to 54 min.
S.-S. Sheu et al. / Biochimica et Biophysica Acta 1762 (2006) 256–265264the high negative internal potential of mitochondria, which
should lead to their concentration in mitochondria.
Preliminary experiments show that these compounds reduce
tert-butylhydroperoxide-induced rat heart mitochondrial depo-
larization, delay the onset of mitochondrial depolarization
caused by H2O2 in neonatal rat ventricular myocytes (Fig. 6)
and striatal neurons, and diminish N-methyl-d-aspartate
(NMDA)-induced ROS generation in striatal neurons. These
results demonstrate that targeting of glutathione and related
thiol-based antioxidants to mitochondria is a useful approach
for preventing oxidative stress-related mitochondrial dysfunc-
tion and as such may find use in the management of a range of
acute and chronic disease processes.
6. Conclusions and perspectives
A decade of research in understanding mechanisms in-
volved in mitochondrial dysfunction related disease states has
clearly implicated overproduction of ROS. This knowledge has
resulted in a range of strategies to develop mitochondrially
targeted antioxidants that prevent ROS-induced mitochondrial
oxidative damage. The compounds described so far show
promise in a range of in vitro systems and one (MitoQ) has
demonstrated activity in a rat model of cardiac ischemia–
reperfusion injury. Preclinical studies in intact rodent models
are, however, needed to evaluate the effectiveness and toxicity
of mitochondrially targeted antioxidants. These compounds do,
to be sure, show that this is a fruitful avenue of investigation
that may lead to clinically useful therapeutic agents.
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